Joseph M Ziegelbauer [1] [2] [3] 5 , Christopher S Sullivan 4 & Don Ganem [1] [2] [3] MicroRNAs (miRNAs) are short noncoding RNAs of cellular 1 and viral origin [2] [3] [4] [5] [6] [7] that post-transcriptionally regulate gene expression through imperfect base pairing to their mRNA targets. Because the recognition sequences of miRNAs for their targets are short and may be discontinuous, bioinformatic prediction of targets is difficult. Here we present an approach to the experimental identification of the mRNA targets of miRNAs encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV). KSHV encodes 17 miRNAs, derived from 12 pre-miRNAs expressed from a single locus during viral latency 2, [5] [6] [7] [8] [9] [10] . We conducted multiple screens that examine small changes in transcript abundance under different conditions of miRNA expression or inhibition and then searched the identified transcripts for seed sequence matches. Using this strategy, we identified BCLAF1, encoding Bcl2-associated factor, as a target for miR-K5, and further analysis revealed that several other KSHV miRNAs also target this gene product. Our results support that this type of expression profiling provides a potentially general approach to the identification of miRNA targets.
To identify host RNA targets of KSHV miRNAs, we proceeded from the observation that RNAs targeted by miRNAs often show small reductions in their steady-state levels [11] [12] [13] [14] . Accordingly, we carried out mRNA expression profiling in B cells and endothelial cells, the main targets of KSHV, under four sets of conditions. First, we examined host mRNA profiles in BJAB B cells transfected with individual KSHV miRNAs versus control miRNAs. Second, we similarly profiled cells stably transduced with retroviruses expressing clusters of KSHV miRNAs. Third, we examined host mRNA expression in primary endothelial cells latently infected with KSHV; these cells express all KSHV miRNAs at their physiologic levels. In each of these cases, we looked for transcripts whose levels decreased upon viral miRNA expression. Fourth, we inhibited 15, 16 individual viral miRNAs in latently-infect BCBL-1 (B lymphoma) cells using antagomirs (Supplementary Fig. 1 online) and searched for transcripts whose levels rose in response to such inhibition (see Supplementary Methods online).
Transcripts whose concentrations were reduced in the presence of a KSHV miRNA and increased in the presence of the cognate antagomir represent candidate miRNA targets. We identified genes with this pattern across all experiments using t-test, fold change, k-means clustering and rank-sum analysis.
Typically, the array results showed only small (less than twofold) changes in mRNA concentrations, which is consistent with previous studies 13, [17] [18] [19] . For each miRNA tested, we identified 10-30 transcripts that passed all four expression filters. Here, we focus on the set of RNA target candidates identified for KSHV miR-K5 (ref. 20) . Figure 1 shows the identities of the host RNAs that passed all the screens for targeting by miR-K5, along with their expression profiles. Next, we used sequence analysis to look for genes with seed-sequence matches for miR-K5 in their 3¢ UTR. Though perfect complementarity may not always be found [21] [22] [23] , it has previously been observed 17 that transcripts with complementary bases at positions 2-8 were more consistently and more strongly downregulated than RNAs with lesser degrees of seed homology. Accordingly, our initial analysis included this additional, very stringent filter for perfect seed complementarity on top of the four expression filters. Among the miR-K5-regulated transcripts, only one gene, that encoding the bcl-2-associated factor (BCLAF1; also called Btf, for bcl2-associated transcription factor), met all five criteria. BCLAF1 was initially identified 24 in a yeast two-hybrid screen for factors binding to the adenovirus E1B-19K protein, an antiapoptotic protein with sequence and functional homologies to the mammalian bcl-2 protein. That report suggested that overexpression of BCLAF1 induces apoptosis in HeLa cells.
To examine its targeting by KSHV miR-K5 in further detail, we first asked whether the concentration of the endogenous BCLAF1 protein could be downregulated by miR-K5 expression, as judged by immunoblotting. Transient transfection of miR-K5 diminished BCLAF1 accumulation in 293 cells (Fig. 2a, left panel) ; the protein was similarly reduced in BJAB B cells stably transduced with a retrovirus coexpressing miRNAs K1, K2, K3, K4 and K5 ( Supplementary  Fig. 2 online) , compared with cells transduced with a retrovirus lacking the miRNA genes (Fig. 2a, center panel) . Notably, we also detected a strong decrease in BCLAF1 in HUVEC cells latently infected with authentic KSHV (Fig. 2a , right panel and Supplementary  Figs. 
2-4 online).
To determine the cis-acting sequence necessary for downregulation, we cloned the BCLAF1 3¢ UTR 25, 26 downstream of a luciferase (LUC) reporter gene and examined LUC expression following cotransfection of this construct with miR-K5 or control microRNA (Fig. 2b) . Although expression of miR-K5 had no effect on the control LUC vector lacking the BCLAF1 3¢ UTR (lane 7), we observed a modest but highly reproducible downregulation of the luciferase reporter containing the BCLAF1 3¢ UTR (lane 2). This region contains a perfect 8-mer target site for the miR-K5 seed 25 , and multimerization of sequences spanning this site strongly enhanced inhibition of luciferase expression by miR-K5 (Fig. 2b, lane 12) . When the seedcomplementary region in the 3¢ UTR was mutated, downregulation by miR-K5 was abolished. (Fig. 2b, lanes 5 and 9) . Co-transfection of the mutant 3¢ UTR plasmid with a mutant of miR-K5 in which complementarity to the UTR was restored resulted in renewed repression of the reporter by the mutant of miR-K5 compared to wild-type miR-K5 (lanes 9, 10). Similarly, mutating two bases in the seed of miR-K5 itself also ablated its ability to inhibit (i) expression of the luciferase reporter construct containing the wild-type BCLAF1 UTR (Fig. 2b , lane 3) and (ii) the accumulation of endogenous BCLAF1 itself (Fig. 2c) . These data unequivocally establish that the BCLAF1 3¢ UTR is directly targeted by miR-K5.
Viruses often encode redundant functions when inactivation of a key host target is critical-for example, multiple viral proteins are deployed to inactivate interferon induction or signaling 27 . For this reason, we wondered whether any other KSHV miRNAs might also target BCLAF1. Consistent with this possibility, we noted that the downregulation of BCLAF1 in latently infected cells, which express all 17 viral miRNAs, is substantially stronger than that observed following expression of miR-K5 alone (Fig. 2a) . Accordingly, we examined the levels of BCLAF1 protein in HUVEC cells transfected with each of the 17 KSHV miRNAs. In addition to miR-K5, several other KSHV miRNAs downregulated this protein reproducibly-notably, miRNAs K9, K10a and K10b (Fig. 3a) . We tested each of these miRNAs for the ability to downregulate the luc + -BCLAF1 3¢ UTR reporter construct (Fig. 3b) . Although miRNAs K9 and K10b repressed the chimera as expected, miR-K10a did not, suggesting that either (i) its targets lie elsewhere in the BCLAF1 transcript or (ii) it modulates BCLAF1 levels indirectly.
To further validate this downregulation, we examined the concentrations of BCLAF1 protein in cells stably expressing miR-K9 from an integrated retroviral vector ( Supplementary Figs. 2 and 4) . miR-K9 expression in this context also downregulated BCLAF1 protein accumulation (Fig. 3c) . Moreover, transient transfection with mutant versions of miRNAsK9 and K10 bearing lesions in their seed sequences impaired the downregulation of BCLAF protein accumulation (Fig. 3d) . Finally, co-transfection of latently infected BCBL-1 cells with antagomirs to miR-K5 or the combination of miRNAs K5, K9, K10a and K10b raised the concentration of endogenous BCLAF1 (Fig. 3e) . Together, these results affirm that downregulation of BCLAF1 by these miRNAs is authentic and specific.
What is the function of BCLAF1 modulation by the viral miRNAs? The reported ability of BCLAF1 to promote apoptosis 24 suggested to us that its downregulation by KSHV miRNAs might be associated with reduced susceptibility to apoptosis. To investigate this, we tested miR-K5 for the ability to impair etoposide-induced caspase activation, as measured by PARP cleavage 28 . miR-K5 inhibited etoposideinduced PARP cleavage, whereas the seed-disrupting mutant of miR-K5 did not (Fig. 4) . Similarly, miRNAs K9, K10a and K10b, which also downregulate BCLAF1, also impaired etoposide-induced caspase activation (Fig. 4c) . Conversely, antagomir inhibition of these miRNAs in latently infected BCBL-1 cells increased PARP cleavage in the absence of etoposide (Fig. 5) .
We noted that under these experimental conditions (nondividing cells plated at confluence) etoposide did not induce visible cell death in HUVEC cells. When the cells were plated at lower density (conditions under which etoposide exposure leads to prominent cell death), we unexpectedly did not observe any protection from apoptosis by KSHV miRNA expression (Fig. 4f) . These findings led us to reexamine the function of BCLAF1, using BCLAF-specific siRNAs to markedly and specifically inhibit its expression (Fig. 4d) . Dividing HUVEC cells were pretreated with siRNAs to BCLAF1, then exposed to etoposide and assayed for apoptosis by caspase activity assays and TUNEL staining (Fig. 4e,f) . This showed that, contrary to expectation, BCLAF1 actually impairs apoptosis-its inhibition sensitizes cells to etoposide-induced cell death (Fig. 4f) . This effect was phenocopied by coexpression of miRNAs K5, K9, K10a and K10b and, to a lesser extent, by miR-K5 alone (Fig. 4e,f) , further affirming their ability to target BCLAF1. It therefore seems that the original inference, derived from overexpression studies, that BCLAF1 is proapoptotic 24 is either highly context dependent or a result of supraphysiological expression. Further experiments will be required to understand the role of BCLAF1 in both uninfected and infected cells. Nonetheless, the functional consequence of this downregulation for KSHV latency can be assessed by examining the effects of BCLAF1 modulation on viral replication. When latently infected cells are chemically induced to lytic KSHV growth, antagonism of miRNAs K5,K9, K10a and K10b is associated with decreased virion production ( Fig. 5a ) and increased BCLAF1 expression (Fig. 5c) . This suggests that BCLAF1 action acts to impair lytic viral replication. If so, then its inhibition by exogenous siRNA should sensitize cells to lytic reactivation. To test this notion, we used SLK endothelial cells latently infected with a recombinant KSHV (rKSHV.214) in which a red fluorescent protein reporter gene has been placed under the control of a strong delayed-early lytic promoter 29 . In the ground state, most cells are latently infected, but approximately 1% spontaneously reactivate, as judged by RFP expression. When ambient levels of BCLAF1 are further reduced by specific RNAi to its mRNA, spontaneous lytic reactivation is doubled (Fig. 5b) . Furthermore, in these same endothelial cells we observed decreased spontaneous lytic reactivation and increased BCLAF1 expression as a result of antagonism of miRNAs K5, K9, K10a and K10b (Fig. 5d) .
Latency is an essential genetic program for herpesviruses, and recent data suggest that some latent viral miRNAs act to stabilize latency by opposing lytic reactivation 30 . The KSHV miRNAs affecting BCLAF1 seem to function differently: they sensitize latently infected cells to stimuli that will induce lytic reactivation. Why might this be useful? A key feature of latency is reversibility-without this feature, latency would be a dead-end pathway. By removing one safety lock on the trigger mechanism governing reactivation, we propose that these viral miRNAs help ensure that KSHV can exit latency when environmental conditions warrant.
Our multiscreen approach to miRNA target identification has both attractive features and limitations. On the positive side, it is very rigorous, and the approach is potentially applicable to host as well as to viral miRNAs. However, it is labor-intensive, and the number and stringency of the tests makes it nearly inescapable that some bona fide targets will be overlooked. For example, BCLAF1 passed only two of the three expression screens as a target for miRNAs K9 and K10b ( Supplementary Fig. 5 online) . Beyond these technical factors, not all miRNA targets will show the modestly diminished transcript accumulation upon which the method is based; in addition, the fact that our screen used both B cells and endothelial cells means that cell typespecific targets will also fail to pass all screens. But by far the most restrictive screen is the bioinformatic one-requiring a perfect 8-mer seed match is surely too stringent for routine use 25 , as many bona fide targets will fail this test (as BCLAF1 did for miRNAs K9, K10a and K10b, Supplementary Fig. 5 ). Of course, the stringency of seed homology as well as the number of positive expression screens required by the experimenter can be relaxed. We anticipate that as our understanding of the nature of hybridization between miRNAs and targets progresses, more refined criteria will replace our stringent but insensitive initial settings.
METHODS
miRNA expression. Synthetic miRNA mimics and inhibitors were from Ambion. BJAB and BCBL-1 cells were electroporated with siPORT system (Ambion) at 30 nM for mimics and 100 nM for inhibitors (RNA harvested 48 and 72 h after transfection, respectively). We transfected 293 and HUVEC cells with Lipofectamine 2000 (Invitrogen) and Dharmacon Dharmafect 1 at 15 and 10 nM, respectively. For stable cell lines, approximately 250 bp of flanking sequence surrounding the miRNA gene(s) were cloned into a gateway vector (Invitrogen) and then transferred into pMSCV-puro. BJAB cells were transduced and selected with puromycin. RNA blots were as described 7 .
Microarrays. Total RNA was harvested with RNAbee, assayed for quality control with Bioanalyzer 2100 (Agilent) and labeled with Low RNA Input Linear Amp kit plus (Agilent). Experimental samples were co-hybridized with labeled Universal Reference RNA (Stratagene) to Agilent Whole Human Genome arrays. Arrays were scanned on GenePix 4000B (Axon), extracted with Agilent Feature Extraction Software and analyzed with Genespring GX. We carried out transient and stable BJAB arrays in duplicate. Transient BJAB datasets were analyzed for genes that met either t-test P value 0.05 cutoff or a combination of relative change and K-means clustering filters. We ranked genes from other datasets in the rank-sum analysis if the ratio was greater or less than 1.0 relative to the negative control miRNA. Sequence analysis. Datasets containing 3¢ UTR sequences were obtained from PACdb (see URLs section below) and TargetScan servers. TargetScan 4.0, miRANDA v1.9 and an ad hoc perl script were used to search transcript sequences for seed matches without conservation analysis.
Luciferase assays. We cloned a Gateway cloning cassette (Invitrogen) into pMIR-Report (Ambion). PCR products containing the BCLAF1 3¢ UTR were cloned into a gateway entry vector and then transferred into the luciferase vector. The mutant was made using the QuikChange mutagenesis system (Stratagene). We transfected 293 cells with firefly reporter TK Renilla and miRNA mimics using Lipofectamine 2000 (Invitrogen). Firefly activity was normalized to TK Renilla internal control. We assayed each transfection in triplicate and carried out at least three independent transfections.
Immunoblotting and apoptosis. After 48 or 72 h of transfection (and 24 h etoposide treatment for apoptosis assays), cells were lysed in RIPA buffer and equal total protein amounts were loaded on gel. Antibodies against BCLAF1 (Bethyl), PARP, cleaved PARP (Cell Signaling), actin and tubulin (Sigma) were detected with HRP-conjugated secondary antibodies using ECL (GE). For TUNEL staining, we used the In situ Cell Death Detection Kit (Roche). See Supplementary Methods and Supplementary Table 1 online for more details.
URLs. PACdb, http://harlequin.jax.org/; MIAME-compliant HUVEC array data, http://puma.princeton.edu/.
Accession codes. NCBI GEO: BJAB and BCBL-1 array data are available under accession number GSE12967.
Note: Supplementary information is available on the Nature Genetics website.
